MONTREAL, November 9, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection announced today the publication of its analyses of the activity of NAPs in various rodent models of HBV infection in the journal Antiviral Research (http://www.sciencedirect.com/science/article/pii/S016635421730596X).
These evaluations in rodent models were conducted independently with investigators expert in these particular models and reported the surprising result that NAPs are inactive in HBV transgenic mice, WHV infected woodchucks and in HBV-infected Scid-Hu mice, despite pronounced accumulation of NAPs in the livers of these species.
The lack of HBsAg response to NAPs in the rodent models tested suggests that the production of subviral particles (SVPs) occurring in these rodent models does not model SVP production in human infection and also provides important clues about the molecular targets underlying the selective inhibition of SVP assembly and release by NAPs. Dr. Vaillant, CSO of Replicor commented, “We can correlate the lack of a HBsAg response to NAPs in these rodent models to differences in HDL metabolism in rodents, where NAPs are inactive, compared to ducks and humans, where NAPs are active, or to altered lipid metabolism in the human chimeras of Scid-Hu mice. These observations continue to focus our efforts on examining the role of apolipoproteins in SVP morphogenesis and their involvement in the antiviral effects of NAPs.”
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of a functional cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.